<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F0FB58FB-EB2B-44DE-991D-CA4C443BED0A"><gtr:id>F0FB58FB-EB2B-44DE-991D-CA4C443BED0A</gtr:id><gtr:firstName>Lucia</gtr:firstName><gtr:surname>Possamai</gtr:surname><gtr:orcidId>0000-0003-1277-2625</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1000344"><gtr:id>F5C19115-68E0-4F4E-B19A-50E762FEE7F2</gtr:id><gtr:title>Identifying genetic susceptibility factors for paracetamol-induced hepatotoxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1000344</gtr:grantReference><gtr:abstractText>Paracetamol is a commonly-used and widely available pain killer. Recent evidence suggests that a third of healthy adults taking the recommended daily dose for 1-2 weeks will develop evidence of liver toxicity. When taken in overdose paracetamol can lead to significant liver toxicity, overt liver failure and even death. In fact paracetamol overdose is the commonest single cause of acute liver failure in the UK and USA and accounts for 200-400 deaths per year in the UK. 
There is a wide range in inter-individual susceptibility to the toxic effects of paracetamol on the liver, suggesting a significant genetic influence. Like humans, mice exhibit features of hepatotoxicty and liver failure when exposed to paracetamol and also display great variety in their response to paracetamol depending on their genetic background. 
By exploiting both naturally occurring and induced genetic variability in mouse models we aim to identify novel genes that influence susceptibility to paracetamol and the subsequent development of acute liver failure.
Greater knowledge of the genetic susceptibility to paracetamol-induced hepatotoxicty will shed light on the molecular mechanisms by which paracetamol and other drugs cause liver damage and ultimately may lead to new therapies for drug-induced liver injury and acute liver failure.</gtr:abstractText><gtr:technicalSummary>Aims &amp;amp; Objectives
To characterise genetic loci and identify candidate genes responsible for the heterogeneous response to acetaminophen (Paracetamol/APAP) and the development of APAP-induced acute liver failure. 

Design
I will exploit both naturally occurring and induced genetic variability in mouse models to identify novel genes that influence APAP susceptibility. The primary focus of my studies will be the characterisation of novel mouse models exhibiting heritable APAP sensitivity generated by an existing ENU mutagenesis programme. To complement these studies I will also complete an inbred strain survey for APAP sensitivity which will inform strain selection for a QTL mapping experiment and allow in-silico studies using established polymorphic SNP resources. 

Methodology
Our research group is undertaking a phenotype-driven ENU-mutagenesis screen for APAP-toxicity, so far nine mutants with heritable APAP sensitivity have been identified. During my Academic Clinical Fellowship I conducted a pilot QTL mapping project that identified an association between APAP-sensitivity and a locus on murine Chromosome 18. 
I will investigate genetic susceptibility to APAP-hepatotoxicity using a number of genetic techniques. I will select two of the most promising ENU mutant lines to take forward for further study. Using established breeding strategies and SNP genotyping I will determine the genomic region associated with the observed phenotype and identify the causative mutation by sequencing candidate genes. Having identified the mutation I will then proceed to explore how it perturbs gene function and promotes APAP sensitivity through 1H-MRS and LC-MS metabonomic studies. Parallel to these investigations, I will survey APAP sensitivity in a panel of 12 inbred mouse strains and use established SNP maps in silico to identify genetic loci associated with susceptibility. Building on the pilot study I conducted and information derived from the inbred strain panel I plan to conduct a further QTL mapping experiment with mouse strains showing extremes of response to APAP.

Scientific and medical opportunities
Recent evidence demonstrates mild hepatotoxicity in patients taking therapeutic doses of APAP. As well as providing new insights into severe APAP toxicity, this project will further our understanding of the genetic causes of this phenomenon. The knowledge generated may lead to novel therapies for acute liver failure and improved recognition of patients experiencing derangement in their liver function due to use of this common analgesic.</gtr:technicalSummary><gtr:fund><gtr:end>2014-12-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>335690</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>67E7395E-BB04-48A9-A367-A17DD54A8ECE</gtr:id><gtr:title>MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bf897582a1845a4071d9f1255d9fcea"><gtr:id>8bf897582a1845a4071d9f1255d9fcea</gtr:id><gtr:otherNames>Triantafyllou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>5a7a25eaa9b833.93618708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>977FE75D-08BC-41E6-B8E2-57A9F0465F1D</gtr:id><gtr:title>Increased Expression of Cytotoxic T-Lymphocyte-Associated Protein 4 by T Cells, Induced by B7 in Sera, Reduces Adaptive Immunity in Patients With Acute Liver Failure.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7a5d86ec727e72eec51517916994333"><gtr:id>c7a5d86ec727e72eec51517916994333</gtr:id><gtr:otherNames>Khamri W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5a7a25eaf062b8.15230822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F66D7AAA-B4B0-4691-8684-C74E72368D9E</gtr:id><gtr:title>Role of monocytes and macrophages in experimental and human acute liver failure</gtr:title><gtr:parentPublicationTitle>World Journal of Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64e9de8423adca3f31ac8dcbbb045304"><gtr:id>64e9de8423adca3f31ac8dcbbb045304</gtr:id><gtr:otherNames>Possamai L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>5a6f06bc09ecb0.19394227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>763148BF-85C4-48E5-909D-32A225AD47DF</gtr:id><gtr:title>The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxicity.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>544a1640c82cc0.14858724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>928D705B-05E3-4625-B538-6ADFF9821EFE</gtr:id><gtr:title>Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>544a16413e1b66.53854701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C5BFC7D-9571-4A2E-9889-77695FF9BD2B</gtr:id><gtr:title>Could targeting secretory leukocyte protease inhibitor be an effective therapeutic option to prevent infections in acute liver failure?</gtr:title><gtr:parentPublicationTitle>Immunotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1750-743X</gtr:issn><gtr:outcomeId>544a164111df92.58466783</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E3C8FFD-3E7F-4280-840F-86A710C9F72C</gtr:id><gtr:title>Role of monocytes and macrophages in experimental and human acute liver failure.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>pm_15831_21_20397256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6324B6AD-5858-4F4F-A8E0-0D619754C4A0</gtr:id><gtr:title>Secretory leukocyte protease inhibitor: a pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e67dbb13d97b20d487ae2d74a6d1c64"><gtr:id>0e67dbb13d97b20d487ae2d74a6d1c64</gtr:id><gtr:otherNames>Antoniades CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>544a1641703868.29997236</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5ECDAD50-B012-4BA2-8404-A160CBCFE84A</gtr:id><gtr:title>Source and characterization of hepatic macrophages in acetaminophen-induced acute liver failure in humans.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e67dbb13d97b20d487ae2d74a6d1c64"><gtr:id>0e67dbb13d97b20d487ae2d74a6d1c64</gtr:id><gtr:otherNames>Antoniades CG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15831_21_22334567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C739C71B-14D7-4FE9-8291-0B0DEAB05B0A</gtr:id><gtr:title>Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*.</gtr:title><gtr:parentPublicationTitle>Critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eee8b47b413a4ed31c63b33f6107a7c2"><gtr:id>eee8b47b413a4ed31c63b33f6107a7c2</gtr:id><gtr:otherNames>Possamai LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0090-3493</gtr:issn><gtr:outcomeId>pm_15831_21_23949472</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1000344</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>